BRIEF-CASI Pharmaceuticals Announces Clinical Hold Of CID-103

Dec 26 (Reuters) - CASI Pharmaceuticals Inc CASI.O:

• CASI PHARMACEUTICALS INC: ANNOUNCES CLINICAL HOLD OF CID-103 FOR ANTIBODY MEDIATED REJECTION (AMR) OF KIDNEY TRANSPLANT

• CASI PHARMACEUTICALS: FDA PLANS TO PROVIDE FORMAL WRITTEN RESPONSE BEFORE STATUTORY DEADLINE

• CASI PHARMACEUTICALS: CID-103 IND APPLICATION SUPPORTING PHASE 1-2 STUDY OF CID-103 IN ADULTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA REMAINS OPEN

• CASI PHARMACEUTICALS: ACCRUAL TO PHASE 1-2 STUDY OF CID-103 EXPECTED TO COMMENCE IN Q1 2025

Further company coverage: CASI.O

((Reuters.Briefs@thomsonreuters.com;))